The survival impact of preoperative FOLFOX for resectable locally advanced rectal cancer: the R-NAC-01 study.
Nobuki IchikawaShigenori HommaTohru FunakoshiMasahiro HattoriMasanori SatoYou KamiizumiKazuyoshi OmoriMasaru NomuraRyoichi YokotaMasahiko KoikeHirofumi KonKeisa TakedaHiroyuki IshizuShinichi MatsuokaKunihiro HiroseTakahisa IshikawaRyohei MurataHiroaki IijimaTadashi YoshidaNozomi MinagawaNorihiko TakahashiAkinobu TaketomiPublished in: Surgery today (2022)
Four courses of mFOLFOX6 chemotherapy before surgery may be a promising treatment strategy for locally advanced rectal cancer. Adjuvant chemotherapy might be needed for cStage III patients, even after four courses of neoadjuvant mFOLFOX6.
Keyphrases
- locally advanced
- rectal cancer
- phase ii study
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- end stage renal disease
- metastatic colorectal cancer
- ejection fraction
- minimally invasive
- newly diagnosed
- chronic kidney disease
- transcription factor
- patients undergoing
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- coronary artery bypass
- patient reported outcomes
- coronary artery disease
- study protocol
- surgical site infection
- combination therapy